- Home
- FOF vs IGMS Comparison
FOF vs IGMS Comparison
Compare FOF & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOF
- IGMS
- Stock Information
- Founded
- FOF 2006
- IGMS 1993
- Country
- FOF United States
- IGMS United States
- Employees
- FOF N/A
- IGMS N/A
- Industry
- FOF Investment Managers
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- FOF Finance
- IGMS Health Care
- Exchange
- FOF Nasdaq
- IGMS Nasdaq
- Market Cap
- FOF 342.8M
- IGMS 348.5M
- IPO Year
- FOF N/A
- IGMS 2019
- Fundamental
- Price
- FOF $13.04
- IGMS $1.71
- Analyst Decision
- FOF
- IGMS Hold
- Analyst Count
- FOF 0
- IGMS 8
- Target Price
- FOF N/A
- IGMS $6.14
- AVG Volume (30 Days)
- FOF 58.7K
- IGMS 783.1K
- Earning Date
- FOF 01-01-0001
- IGMS 03-06-2025
- Dividend Yield
- FOF 9.07%
- IGMS N/A
- EPS Growth
- FOF N/A
- IGMS N/A
- EPS
- FOF N/A
- IGMS N/A
- Revenue
- FOF N/A
- IGMS $2,918,000.00
- Revenue This Year
- FOF N/A
- IGMS $23.57
- Revenue Next Year
- FOF N/A
- IGMS $192.36
- P/E Ratio
- FOF N/A
- IGMS N/A
- Revenue Growth
- FOF N/A
- IGMS 57.64
- 52 Week Low
- FOF $9.59
- IGMS $1.59
- 52 Week High
- FOF $11.75
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- FOF 61.24
- IGMS 19.36
- Support Level
- FOF $12.56
- IGMS $1.59
- Resistance Level
- FOF $13.16
- IGMS $2.06
- Average True Range (ATR)
- FOF 0.17
- IGMS 0.41
- MACD
- FOF 0.05
- IGMS -0.25
- Stochastic Oscillator
- FOF 79.17
- IGMS 2.18
About FOF Cohen & Steers Closed-End Opportunity Fund Inc.
Cohen & Steers Closed-end Opp Fd Inc is a diversified, closed-ended management investment company. Its investment objective is to achieve a total return, consisting of high current income and potential capital appreciation.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.